O
CMPX icon

OrbiMed’s Compass Therapeutics CMPX Stock Holding History

OrbiMed’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.5M Hold
15,219,994
– – 1.6% 16
2025
Q4 		$81.7M Hold
15,219,994
– – 1.67% 19
2025
Q3 		$53.3M Hold
15,219,994
– – 1.25% 25
2025
Q2 		$39.6M Sell
15,219,994
-7,142,856
-32% -$14.7M 0.99% 28
2025
Q1 		$42.5M Hold
22,362,850
– – 1.01% 28
2024
Q4 		$32.4M Hold
22,362,850
– – 0.67% 41
2024
Q3 		$41.1M Hold
22,362,850
– – 0.75% 40
2024
Q2 		$22.4M Hold
22,362,850
– – 0.44% 58
2024
Q1 		$44.3M Hold
22,362,850
– – 0.81% 42
2023
Q4 		$34.9M Hold
22,362,850
– – 0.7% 51
2023
Q3 		$44.1M Hold
22,362,850
– – 0.94% 40
2023
Q2 		$71.1M Hold
22,362,850
– – 1.29% 29
2023
Q1 		$73.1M Hold
22,362,850
– – 1.44% 20
2022
Q4 		$112M Buy
22,362,850
+402,000
+2% +$1.6M 2.15% 14
2022
Q3 		$50.1K Hold
21,960,850
– – 0.93% 40
2022
Q2 		$58.2K Buy
21,960,850
+317,875
+1% +$690K 1.05% 33
2022
Q1 		$29.7M Hold
21,642,975
– – 0.48% 54
2021
Q4 		$68.6M Buy
+21,642,975
New +$71.8M 0.88% 39

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OrbiMed's CMPX Position: Q1 2026 in Review

OrbiMed held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 15,219,994 shares worth $80.5M. The position accounts for 1.6% of the portfolio, ranked #16.

OrbiMed first reported a position in CMPX in Q4 2021 and has held it in 18 quarters since. The position peaked at $112M in Q4 2022. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • OrbiMed held 15,219,994 shares of Compass Therapeutics worth $80.5M as of Q1 2026.
  • OrbiMed left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up 1.6% of OrbiMed's portfolio in Q1 2026, its #16 holding.
  • OrbiMed first reported a position in Compass Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • OrbiMed's Compass Therapeutics position peaked at $112M in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.